Open-Label Disulfiram for Methamphetamine Dependence
Information source: University of Arkansas
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Methamphetamine Dependence
Intervention: Disulfiram (Drug)
Phase: Phase 1/Phase 2
Status: Completed
Sponsored by: University of Arkansas Official(s) and/or principal investigator(s): Alison Oliveto, PhD, Principal Investigator, Affiliation: University of Arkansas
Summary
This 8 week, open-label pilot clinical trial will examine the safety and tolerability of
disulfiram at 250 mg/day in up to fifteen methamphetamine dependent individuals. After
undergoing screening procedures (approximately one week), eligible subjects will enter the
study proper attend clinic every weekday during week 1 of the trial in order to receive the
disulfiram under observation and complete assessments. Then subjects will receive weekly
blister packs of medication and attend clinic thrice weekly during weeks 2-6. During weeks
7-8, subjects no longer take disulfiram, are followed for two weeks, then referred to
treatment elsewhere, if desired. Urine samples will be obtained and a disulfiram
side-effects checklist will be completed thrice-weekly. Self-reported drug use, craving and
mood ratings will be completed weekly. All subjects undergo cognitive behavioral therapy.
Adjunctive contingency management procedures will be utilized to enhance retention. The
primary outcomes of interest include retention, side-effects, and drug use. Our hypothesis
is that disulfiram will be well tolerated in this population.
Clinical Details
Official title: Open-Label Pilot Study of Disulfiram for Methamphetamine Dependence
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Side Effects Checklist
Secondary outcome: Proportion of Amphetamine-positive Urine Samples
Detailed description:
This 8 week, open-label pilot clinical trial will examine the safety and tolerability of
disulfiram at 250 mg/day in up to fifteen methamphetamine dependent individuals. After
undergoing screening procedures (approximately one week), eligible subjects will enter the
study proper attend clinic every weekday during week 1 of the trial in order to receive the
disulfiram under observation and complete assessments. Then subjects will receive weekly
blister packs of medication and attend clinic thrice weekly during weeks 2-6. During weeks
7-8, subjects no longer take disulfiram, are followed for two weeks, then referred to
treatment elsewhere, if desired. Urine samples will be obtained and a disulfiram
side-effects checklist will be completed thrice-weekly. Self-reported drug use, craving and
mood ratings will be completed weekly. All subjects undergo cognitive behavioral therapy.
Adjunctive contingency management procedures will be utilized to enhance retention. The
primary outcomes of interest include retention, side-effects, and drug use. Results of this
study will provide initial safety and drug use data for grant applications proposing to
examine the clinical efficacy of disulfiram or similar agents to for treating
methamphetamine dependence under placebo-controlled, double-blind conditions.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18-65 years old
- not currently enrolled in a treatment program
- subjects must have a history of methamphetamine use with recent use confirmed by a
positive urine toxicology screen for amphetamines during the month prior to study
entry
- subjects must meet DSM-IV criteria for amphetamine dependence as assessed by the
substance abuse section of the Structured Clinical Interview for DSM-IV (SCID)
- women of childbearing age must have a negative pregnancy test to enroll in this
study, agree to monthly pregnancy testing, and agree to use appropriate forms of
birth control for the duration of the study.
Exclusion Criteria:
- current diagnosis of alcohol physical dependence
- significant medical conditions such as abnormal liver function (e. g., laboratory
findings on ALT or AST greater than three times normal), active hepatitis,
uncontrolled hypertension, a current cardiac condition or high risk of cardiovascular
disease (see section c. 1), seizure disorders, or another significant underlying
medical condition which would contraindicate disulfiram treatment
- meeting DSM-IV psychiatric classifications for schizophrenia, bipolar disorder, or
other psychotic disorders
- exhibiting current suicidality or homicidality
- pregnancy or breastfeeding
- current use of a prescribed psychotropic medication (e. g., antidepressants,
anxiolytics, antipsychotics, anticonvulsants, etc.) which cannot be discontinued
- current use of medications such as anticoagulants, isoniazid, metronidazole,
clotrimazole, and paraldehyde
Locations and Contacts
University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States
Additional Information
Starting date: August 2008
Last updated: January 20, 2012
|